Bristol-Myers Squibb
BMY
2,516 hedge funds and large institutions have $119B invested in Bristol-Myers Squibb in 2022 Q1 according to their latest regulatory filings, with 212 funds opening new positions, 990 increasing their positions, 996 reducing their positions, and 114 closing their positions.
86% more first-time investments, than exits
New positions opened: 212 | Existing positions closed: 114
33% more funds holding in top 10
Funds holding in top 10: 64 → 85 (+21)
20% more capital invested
Capital invested by funds: $99.1B → $119B (+$19.5B)
20% more call options, than puts
Call options by funds: $2.4B | Put options by funds: $2B
4.63% more ownership
Funds ownership: 72.22% → 76.85% (+4.6%)
3% more funds holding
Funds holding: 2,445 → 2,516 (+71)
1% less repeat investments, than reductions
Existing positions increased: 990 | Existing positions reduced: 996
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$1.54B |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$836M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$705M |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
+$293M |
| 5 |
Goldman Sachs
New York
|
+$276M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$512M |
| 2 |
Berkshire Hathaway
Omaha,
Nebraska
|
-$324M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$268M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$242M |
| 5 |
Nordea Investment Management
Stockholm,
Sweden
|
-$183M |
BMY Hedge Fund Activity: Q1 2022 in Review
2,516 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q1 2022, worth a combined $119B — up 20% from $99.1B a quarter earlier.
Buyers outnumbered sellers: 212 funds opened new BMY positions and 114 closed out — a net gain of 98 holders — while 990 added to existing stakes and 996 trimmed.
The largest buyer was Capital International Investors, opening a new position worth an estimated $1.54B. The largest seller was Wellington Management Group, cutting an estimated $512M.
- 2,516 institutional investors held Bristol-Myers Squibb (BMY) as of Q1 2022, up from 2,445 in Q4 2021.
- Funds reported $119B of Bristol-Myers Squibb stock for Q1 2022, up 20% quarter-over-quarter.
- 212 funds opened new Bristol-Myers Squibb positions in Q1 2022 and 114 closed out, a net change of +98 holders.
- The largest Bristol-Myers Squibb buyer in Q1 2022 was Capital International Investors, an estimated $1.54B added.
- The largest Bristol-Myers Squibb seller in Q1 2022 was Wellington Management Group, an estimated $512M sold.
Based on aggregated 13F filings for Q1 2022.